CEACAM5 and colorectal carcinoma: Signatera was approved by the Food and Drug Administration (FDA) for stage II and III CRC patients for two intended uses: (1) patient risk stratification after surgical resection, to inform adjuvant treatment decisions, and (2) recurrence monitoring with the same frequency as carcinoembryonic antigen (CEA), in patients with a previous cancer diagnosis but no ongoing evidence of disease.